<DOC>
	<DOCNO>NCT02051608</DOCNO>
	<brief_summary>Part 1 multicenter , randomize , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety gantenerumab participant mild Alzheimer disease . Participants randomize receive either gantenerumab subcutaneously every 4 week placebo subcutaneously every 4 week . Approved Alzheimer medication allow stable dose 3 month prior screen . Part 2 open-label extension ( OLE ) . A positron emission tomography ( PET ) image substudy conduct within main study . Eligible participant provide separate inform consent undergo PET imaging scan use radioligand florbetapir pharmacodynamic measure change brain amyloid load time . The substudy 's target sample size 100 participant arm main study .</brief_summary>
	<brief_title>A Study Gantenerumab Participants With Mild Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Clinical diagnosis probable mild Alzheimer disease ( AD ) base National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria major NCD base whether receive AD approve medication Cerebral spinal fluid ( CSF ) result consistent presence amyloid pathology Availability person ( 'caregiver ' ) investigator 's judgment frequent sufficient contact participant , able provide accurate information regard participant 's cognitive functional ability Fluency language test use study site Willingness ability complete aspect study Adequate visual auditory acuity , investigator 's judgment , sufficient perform neuropsychological testing ( eye glass hear aid permit ) If currently receive approve medication AD , dose regimen must stable 3 month prior screen Agreement participate research study duration trial associate substudies PART 2 All participant randomize actively participate study eligible Part 2 Dementia neurocognitive disorder ( NCD ) due condition AD , include , limited , frontotemporal dementia , Parkinson disease , dementia Lewy body , Huntington disease , vascular dementia History presence clinically evident vascular disease potentially affect brain opinion investigator potential affect cognitive function History presence stroke within past 2 year document history transient ischemic attack within last 12 month History presence systemic autoimmune disorder potentially cause progressive neurologic disease associate cognitive deficit History schizophrenia , schizoaffective disorder , bipolar disorder Alcohol and/or substance use disorder ( accord DSM5 ) within past 2 year ( nicotine use allow ) History presence atrial fibrillation Within last 2 year , unstable clinically significant cardiovascular disease ( e.g. , myocardial infarction , angina pectoris , cardiac failure New York Heart Association Class II high ) Uncontrolled hypertension Chronic kidney disease Impaired hepatic function PET imaging substudy , addition : Prior participation research study clinical care within last year total radiation exposure would exceed local national annual limit Part 2 Participants discontinue study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>